Lipocine Inc logo

Lipocine Inc(LPCN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$1.71
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LPCN

11/13/2026: LPCN (2-star) is currently NOT-A-BUY. Pass it for now.

Lipocine Inc is a commercial-stage biopharmaceutical company that leverages proprietary drug delivery technologies to develop treatments for endocrine and metabolic disorders. Its most significant milestone is the FDA approval of TLANDO, its flagship oral testosterone replacement therapy, which serves as its primary revenue driver. While the company has validated its technology and entered the commercial market, it faces significant risks including intense competition from large pharmaceutical incumbents, the need for successful commercial execution, and potential reliance on future financing. Lipocine may suit investors who are comfortable with the high volatility and speculative nature of small-cap biotech, particularly those monitoring the successful uptake of its products.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers growth potential through pipeline success but remains in a high-risk, speculative phase.
Momentum investorMixed fitMomentum is highly conditional on positive clinical data readouts or commercial sales surprises.
Value investorWeak fitThe lack of consistent profitability and reliance on dilution makes this a poor fit for traditional value strategies.
Dividend investorWeak fitThe company is not cash-flow positive and does not pay dividends.
Low-risk investorWeak fitHigh price volatility and binary clinical outcomes make this unsuitable for risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap biotech stocks frequently experience significant price swings based on news flow.
Valuation riskMedium / highValuations are often speculative and based on future potential rather than current fundamentals.
Competition risk (Pharma incumbents)HighEstablished players dominate the market share and have superior resources.
Business qualityMediumThe company has a validated platform but limited operational scale.
Dividend incomeLow / noneNo dividends are paid to shareholders.
Execution riskHighSuccess depends on commercializing TLANDO and advancing the pipeline.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 18.94M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) 3.9M shares
Beta 0.5
52 Weeks Range 1.36 - 12.37
Updated Date 11/14/2026
52 Weeks Range 1.36 - 12.37
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.32

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 133.61%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
LPCN receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft company fundamentals, and weak price momentum.

Company Fundamentals

★★★★★
LPCN has soft overall fundamentals (2 stars), with soft financial health, weak growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-115371.9%), weak cash generation (FCF margin -493.8%), negative revenue growth (-82.3%).

Financial Health Rating

★★★★★
LPCN's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 84.4%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
LPCN's growth profile is soft, with the least-weak measure being revenue growth at -82.3% FY2025 versus FY2024. By comparison, while earnings growth (-115371.9%, negative) and free-cash-flow growth (-644.3%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 36.2% (moderate) and 58.8% of outstanding shares are publicly tradable (solid). Insider ownership of 4.96% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Squadron Capital Management LLC 9.82%
Ikarian Capital, LLC 6.17%
Eversept Partners, LP 3.58%
Vanguard Capital Management, LLC 2.80%
Acadian Asset Management LLC 2.07%

Unit Economics (Per $1K Revenue)

★★★★★
LPCN generates approximately $-3,343 of gross profit, $-5,247 of operating income, and $-4,938 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
LPCN has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product SalesRevenue generated from the sale of TLANDO.The company earns money primarily by selling its approved drug to patients and pharmacies.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 5.64
Enterprise Value -3.52M
Price to Sales(TTM) 12.06
Enterprise Value -3.52M
Price to Sales(TTM) 12.06
Enterprise Value to Revenue 0.62
Enterprise Value to EBITDA 153.43
Shares Outstanding 11.07M
Shares Floating 6.51M
Shares Outstanding 11.07M
Shares Floating 6.51M
Percent Insiders 4.96
Percent Institutions 36.24

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.